Hetero emerges 1st in world to bag WHO PQ for generic version of Pfizer’s Covid-19 oral drug Paxlovid

Pharma player Hetero Group on Monday said it has emerged as the first in the world to receive the World Health Organisation’s prequalification of medicines programme (WHO-PQ) for its generic version of Covid-19 oral antiviral treatment candidate Nirmatrelvir, which along with Ritonavir is used as part of Pfizer’s Paxlovid. 

Leave a Comment

Your email address will not be published. Required fields are marked *